ASGE Postgraduate Course at ACG 2022: Expanding the Scope of Fundamental and Advanced Endoscopy | October 2022-Point Counterpoint: Malignant G astric Outlet Obstruction - Duodenal Stenting Is the Time-Tested Therapy

Point Counterpoint: Malignant G astric Outlet Obstruction - Duodenal Stenting Is the Time-Tested Therapy

Video Transcription

Video Summary

In this pre-recorded lecture, Philip G presents a rebuttal to argue that duodenal stenting remains a viable therapy in 2022 for patients with pancreatic cancer and malignant gastric outlet obstruction. He highlights that surgery is currently the only potential curative treatment for pancreatic cancer, which has a poor prognosis. Duodenal stenting has a long track record of efficacy, with studies showing similar success rates and outcomes compared to surgical bypass options. Furthermore, he questions the adoption and proficiency of EUSGJ, an alternative endoscopic procedure, due to limited availability and the steep learning curve. He also suggests that robotic gastrointestinaloscopy may present a more viable competitor to EUSGJ. Overall, he emphasizes that management decisions should be tailored to individual patients in a multidisciplinary approach. Acknowledging the limitations of both duodenal stenting and EUSGJ, he concludes that they serve different purposes and should not be seen as exclusively competing options.

Asset Subtitle

Phillip S. Ge, MD

Keywords

duodenal stenting

pancreatic cancer

malignant gastric outlet obstruction

surgical bypass

EUSGJ